Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk.

Subjects

Subjects :

Cardiovascular Diseases etiology
Heart Disease Risk Factors
Humans
Risk Factors
Cardiovascular Diseases prevention & control
Diabetes Mellitus drug therapy
Sodium-Glucose Transporter 2 Inhibitors pharmacology
Glucagon-Like Peptide-1 Receptor Agonists

Details

Language :

English

ISSN :

1522-9645

Volume :

41

Issue :

2

Database :

MEDLINE

Journal :

European heart journal

Publication Type :

Academic Journal

Accession number :

31800036

Full Text :

https://doi.org/10.1093/eurheartj/ehz853